Ardigen joins the OASIS Consortium to advance multi-omics safety assessment

Topic:

Ardigen has proudly joined the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium as a tech partner and collaborator. This partnership positions Ardigen alongside prominent industry leaders (such as Amazon Web Services, Axiom Bio, BioSpyder, EU-OPENSCREEN, Nomic Bio, Revvity, and Xellar Biosystems) along with many government and academic organizations in a collaborative effort to push the boundaries of multi-omics technologies for safety assessment.

Convened in July 2023 by the Health and Environmental Sciences Institute (HESI) in collaboration with the Broad Institute of Harvard and MIT, OASIS is a cutting-edge initiative supported by the Massachusetts Life Sciences Center (MLSC). The consortium brings together over 60 global experts from academia, industry, government, and NGOs, creating a unique multi-disciplinary ecosystem. With its focus on integrating Cell Painting, transcriptomics, and proteomics across various cell models, OASIS aims to develop innovative tools for assessing chemical safety, with hepatotoxicity as the initial test case.

Ardigen’s role as a tech partner involves contributing our expertise in data analysis, including our extensive experience and cutting-edge approaches to analyzing Cell Painting data. Ardigen will contribute to all consortium activities and the broader HESI Emerging Systems Toxicology for the Assessment of Risk (eSTAR) initiative. Additionally, Ardigen and other industry partners have the opportunity to add compounds of interest to the studies, enhancing the collaborative potential of the research.

 

The OASIS Consortium is tackling some of the biggest challenges in toxicology and drug development. Ardigen’s partnership with OASIS emphasizes its commitment to harnessing data-driven technologies for advancing drug discovery and development research and insights into human health. Together with its partners, Ardigen looks forward to contributing to the development of next-generation safety assessment methods and furthering innovation in toxicology.

You might be also interested in:

The role of AI CROs in the next wave of biopharma transformation)
AI CROs and the Pharma Shift: The Next Wave of Drug Discovery Innovation
AI hit-to-lead optimization for drug discovery
AI brain neurological diseases
Uncovering novel targets and approaches to treating neurological diseases

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!